Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain
Clin. transl. oncol. (Print)
; 13(12): 869-877, dic. 2011. tab, ilus
Artigo
em Inglês
| IBECS
| ID: ibc-125995
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
INTRODUCTION Sunitinib, an oral, multitargeted receptor tyrosine kinase inhibitor, delays disease progression, with a median overall survival (OS) of more than 2 years, improves quality of life and is becoming the first-line standard of care for metastatic renal carcinoma (mRCC). PURPOSE To assess the economic value of sunitinib as fi rst-line therapy in mRCC within the Spanish healthcare system. METHODS An adapted Markov model with a 10-year time horizon was used to analyse the cost effectiveness of sunitinib vs. sorafenib (SFN) and bevacizumab/interferon-α (BEV/IFN) as first-line mRCC therapy from the Spanish third-party payer perspective. Progression-free survival (PFS) and OS data from sunitinib, SFN and BEV/IFN pivotal trials were extrapolated to project survival and costs in 6-week cycles. Results, in progression-free life-years (PFLY), life years (LY) and quality-adjusted life-years (QALY) gained, expressed as incremental cost-effectiveness ratios (ICER) with costs and benefits discounted annually at 3%, were obtained using deterministic and probabilistic analyses. RESULTS Sunitinib was more effective and less costly than both SFN (gains of 0.52 PFLY, 0.16 LY, 0.17 QALY) and BEV/IFN (gains of 0.19 PFLY, 0.23 LY, 0.16 QALY) with average cost savings/patients of 1,124 and 23,218, respectively. Using a willingness-to-pay (WTP) threshold of 50,000/QALY, sunitinib achieved an incremental net benefit (INB) of 9,717 and 31,211 compared with SFN and BEV/IFN, respectively. At this WTP, the probability of sunitinib providing the highest INB was 75%. CONCLUSION Our analysis suggests that sunitinib is a costeffective alternative to other targeted therapies as first-line mRCC therapy in the Spanish healthcare setting (AU)
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Contexto em Saúde:
Agenda de Saúde Sustentável para as Américas
Problema de saúde:
Objetivo 4: Financiamento para a saúde
Base de dados:
IBECS
Assunto principal:
Pirróis
/
Carcinoma de Células Renais
/
Ensaios Clínicos como Assunto
/
Interferon-alfa
/
Modelos Econômicos
/
Inibidores da Angiogênese
/
Indóis
/
Neoplasias Renais
Tipo de estudo:
Estudo de avaliação
/
Avaliação econômica em saúde
/
Estudo prognóstico
Aspecto:
Preferência do paciente
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2011
Tipo de documento:
Artigo
Instituição/País de afiliação:
Hospital Clínico San Carlos/Spain
/
Hospital Universitario 12 de Octubre/Spain
/
Hospital Universitario Madrid Norte Sanchinarro/Spain
/
Hospital Universitario Marqués de Valdecilla/Spain
/
Hospital de Santa Creu i Sant Pau/Spain
/
Pfizer España/Spain
/
United Biosource Corporation/UK